Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Celularity IncCELU · Entity 7145 | Director | June 14, 2023 | June 16, 2023 |
| ELK CREEK RESOURCES CORP.GXIIU · Entity 115354 | Director | March 17, 2021 | March 17, 2021 |
| Neostellar Capital Corp.SSSS · Entity 6085 | Director | June 10, 2026 | June 12, 2026 |
| Soren Acquisition Corp.SORN · Entity 5795 | Director | January 06, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Celularity Inc
Report date June 14, 2023 · Filed June 16, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 236,066 |
Reported balance
After 2023-06-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 199,921 · Balance 236,066 F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2: Includes 199,921 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2033-06-14 | Direct | 277,778 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 277,778 · Balance 277,778 F3: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
F2: Includes 199,921 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
F3: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
ELK CREEK RESOURCES CORP.
Report date March 17, 2021 · Filed March 17, 2021
This filing explicitly reported no securities owned.
Neostellar Capital Corp.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,950 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 3,536 · Balance 68,950 F1: Relates to restricted shares granted under the SuRo Capital Corp. Second Amended and Restated 2019 Equity Incentive Plan, which are scheduled to vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being June 10, 2027) and (ii) the date of SuRo Capital Corp.'s annual meeting of stockholders that is closest to the first anniversary of the award date. In connection with the approval of the Company's externalization by its stockholders, the Board of Directors of the Company may, in its sole discretion, accelerate the vesting of these shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Relates to restricted shares granted under the SuRo Capital Corp. Second Amended and Restated 2019 Equity Incentive Plan, which are scheduled to vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being June 10, 2027) and (ii) the date of SuRo Capital Corp.'s annual meeting of stockholders that is closest to the first anniversary of the award date. In connection with the approval of the Company's externalization by its stockholders, the Board of Directors of the Company may, in its sole discretion, accelerate the vesting of these shares.
Soren Acquisition Corp.
Report date January 06, 2026 · Filed January 07, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fibrocell Science, Inc.
Report date December 13, 2019 · Filed December 13, 2019
Section 16 reporting ended · disclosed 2019-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 1
1 source rowRow 1 · 2019-12-13 · Disposition to issuer · Disposed 600 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $390.00 · Expires 2020-04-01 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-13 · Disposition to issuer · Disposed 534 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $232.50 · Expires 2021-01-14 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-13 · Disposition to issuer · Disposed 534 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.50 · Expires 2023-02-21 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-13 · Disposition to issuer · Disposed 534 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.35 · Expires 2023-07-19 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-13 · Disposition to issuer · Disposed 1,600 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $81.60 · Expires 2025-06-24 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-13 · Disposition to issuer · Disposed 2,400 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $14.25 · Expires 2026-06-22 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-13 · Disposition to issuer · Disposed 2,400 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.55 · Expires 2027-06-22 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-12-13 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.36 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-12-13 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.94 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-12-13 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
| Options to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $62.10 · Expires 2024-06-20 | Direct | 0 |
Reported balance
After 2019-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-13 · Disposition to issuer · Disposed 1,200 · Balance 0 F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
F2: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 18:55 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 3,536 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-028554 · ownership.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,950 F1 · kind: Relates to restricted shares granted under the SuRo Capital Corp. Second Amended and Restated 2019 Equity Incentive Plan, which are scheduled to vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being June 10, 2027) and (ii) the date of SuRo Capital Corp.'s annual meeting of stockholders that is closest to the first anniversary of the award date. In connection with the approval of the Company's externalization by its stockholders, the Board of Directors of the Company may, in its sole discretion, accelerate the vesting of these shares. Read SEC document |
| May 28, 2025 Filed May 30, 2025 17:23 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-055012 · tm2516423-3_4seq1.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,414 F1 · kind: Relates to restricted shares granted under the SuRo Capital Corp. Second Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being May 28, 2026) and (ii) the date of SuRo Capital Corp.'s (the "Company's") annual meeting of stockholders that is closest to the first anniversary of the award date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 16:07 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 12,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-069638 · tm2416744-2_4seq1.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,602 F1 · kind: Relates to restricted shares granted under the SuRo Capital Corp. Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being June 5, 2025) and (ii) the date of SuRo Capital Corp.'s (the "Company's") annual meeting of stockholders that is closest to the first anniversary of the award date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:02 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 277,778 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0000899243-23-015879 · doc4.xml · derivative · entry 2 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,778 Underlying: Class A Common Stock · 277,778 shares Expires 2033-06-14 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:02 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 199,921 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015879 · doc4.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,066 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 199,921 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:14 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 15,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-067713 · tm2317630-3_4seq1.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,554 F1 · kind: Relates to restricted shares granted under the SuRo Capital Corp. Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being May 31, 2024) and (ii) the date of SuRo Capital Corp.'s (the "Company's") annual meeting of stockholders that is closest to the first anniversary of the award date. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:54 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 54,152 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000899243-22-026194 · doc4.xml · derivative · entry 2 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,152 Underlying: Class A Common Stock · 54,152 shares Expires 2032-07-13 F2 · derivative.exercise_date: This option is granted under the Issuer's 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 20:54 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 36,145 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026194 · doc4.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,145 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 12:15 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 6,684 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-067949 · tm2217669-3_4seq1.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,539 F1 · kind: Relates to restricted shares granted under the SuRo Capital Corp. Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of (i) the first anniversary of the award date (with such first anniversary being June 1, 2023) and (ii) the date of SuRo Capital Corp.'s (the "Company's") annual meeting of stockholders that is closest to the first anniversary of the award date. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:11 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 56,053 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001213900-21-047752 · ownership.xml · derivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,053 Underlying: Class A Common Stock · 56,053 shares Expires 2031-09-09 F1 · derivative.exercise_date: This option shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, September 9, 2021, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| July 09, 2021 Filed Jul 13, 2021 19:05 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 3,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-091811 · tm2122112d2_4.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,397 F1 · kind: Relates to restricted shares granted under the SuRo Capital Corp. Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of the (i) first anniversary of the award date (with such first anniversary being July 9, 2022) and (ii) date of SuRo Capital Corp.'s (the "Company") annual meeting of stockholders that is closest to the first anniversary of the award date. F1 · shares: Relates to restricted shares granted under the SuRo Capital Corp. Amended and Restated 2019 Equity Incentive Plan, which vest in full on the earlier of the (i) first anniversary of the award date (with such first anniversary being July 9, 2022) and (ii) date of SuRo Capital Corp.'s (the "Company") annual meeting of stockholders that is closest to the first anniversary of the award date. F2 · balance_after: This total includes (i) 1,040 shares of the Company's common stock and (ii) 1,147 shares of the Company's common stock acquired in connection with a dividend of the Company. Read SEC document |
| July 02, 2020 Filed Jul 2, 2020 17:36 UTC | Neostellar Capital Corp. SSSS · Entity 6085 | GrantCommon Stock | 5,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-080695 · tm2023968d2_4.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,440 F1 · kind: Restricted shares issued under SuRo Capital Corp.'s (the "Company") Amended and Restated 2019 Equity Incentive Plan. F2 · kind: Such restricted shares shall vest in full on the first anniversary of the award date (with such first anniversary being July 2, 2021) (or, if earlier, the Company's annual meeting of stockholders that is closest to the first anniversary of the award date). F2 · balance_after: Such restricted shares shall vest in full on the first anniversary of the award date (with such first anniversary being July 2, 2021) (or, if earlier, the Company's annual meeting of stockholders that is closest to the first anniversary of the award date). Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,000 | Not disclosed Strike: $1.94 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 11 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2029-06-12 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,000 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 10 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2028-06-19 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 6,000 | Not disclosed Strike: $16.55 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 9 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2027-06-22 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,400 | Not disclosed Strike: $14.25 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 8 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2026-06-22 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,400 | Not disclosed Strike: $81.60 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 7 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,400 shares Expires 2025-06-24 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOptions to purchase common stock · Derivative | 1,200 | Not disclosed Strike: $62.10 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 6 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,200 shares Expires 2024-06-20 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,600 | Not disclosed Strike: $82.35 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 5 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,600 shares Expires 2023-07-19 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 534 | Not disclosed Strike: $52.50 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 4 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 534 shares Expires 2023-02-21 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 534 | Not disclosed Strike: $232.50 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 3 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 534 shares Expires 2021-01-14 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerOption to Purchase Common Stock · Derivative | 534 | Not disclosed Strike: $390.00 | Not disclosed |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · derivative · entry 2 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 534 shares Expires 2020-04-01 F2 · price: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, outstanding options, whether vested or not, became fully vested in accordance with the terms of the Merger Agreement and were canceled in exchange for a cash payment equal to the number of shares of Company common stock underlying the options multiplied by the excess of the per share merger consideration of $3.00 over the per share exercise price. Read SEC document |
| December 13, 2019 Filed Dec 13, 2019 16:09 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | Disposition to issuerCommon Stock | 600 | $3.00 | $1,800.00 |
DisclosureSEC source: 0001628280-19-015073 · wf-form4_157627135662849.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:33 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | GrantOption to Purchase Common Stock · Derivative | 12,000 | Not disclosed Strike: $1.94 | Not disclosed |
DisclosureSEC source: 0001628280-19-008007 · wf-form4_156054437858719.xml · derivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-12 F2 · price: The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors. F1 · derivative.exercise_date: 50% of the shares vest and become exercisable on the earlier of (x) June 12, 2020 and (y) the date of the Company's 2020 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 12, 2021 and (y) the date of the Company's 2021 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 16:12 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | GrantOption to Purchase Common Stock · Derivative | 6,000 | Not disclosed Strike: $2.36 | Not disclosed |
DisclosureSEC source: 0001628280-18-008179 · wf-form4_152961191400063.xml · derivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2028-06-19 F2 · price: The options were issued in connection with the reporting person's service to the Company as a member of its Board of Directors. F1 · derivative.exercise_date: 50% of the shares vest and become exercisable on the earlier of (x) June 19, 2019 and (y) the date of the Company's 2019 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 19, 2020 and (y) the date of the Company's 2020 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates. Read SEC document |
| August 14, 2017 Filed Aug 14, 2017 20:26 UTC | Neostellar Capital Corp. GSVC · Entity 6085 | PurchaseCOMMON STOCK | 6,000 | $4.45 | $26,700.00 |
DisclosureSEC source: 0001144204-17-043321 · v473332_4.xml · nonDerivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 19:34 UTC | Fibrocell Science, Inc. FCSC · Entity 153085 | GrantOption to Purchase Common Stock · Derivative | 30,000 | Not disclosed Strike: $3.31 | Not disclosed |
DisclosureSEC source: 0001628280-17-006736 · wf-form4_149852004936184.xml · derivative · entry 1 Mazur Marc · CIK 0001361226 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-22 F2 · price: The options were issued in connection with the reporting person's employment service to the Company. F1 · derivative.exercise_date: 50% of the shares vest and become exercisable on the earlier of (x) June 22, 2018 and (y) the date of the Company's 2018 Annual Meeting of Stockholders, and the remaining 50% of the shares vest and become exercisable on the earlier of (x) June 22, 2019 and (y) the date of the Company's 2019 Annual Meeting of Stockholders, in each case, subject to the grantee's continued service through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.